1. P1‐043: INHIBITION OF AMYLOID OLIGOMER FORMATION BY ENDOGENOUS METABOLITE OF ALZ‐801/TRAMIPROSATE IN THE HUMAN BRAIN: DISCOVERY AND CHARACTERIZATION OF 3‐SPA IN NORMAL SUBJECTS AND ALZHEIMER'S DISEASE PATIENTS. (1st July 2019) Authors: Hey, John; Tolar, Martin; Abushakra, Susan; Power, Aidan; Yu, Jeremy; Kocis, Petr; Vyhnalek, Martin; Hort, Jakub Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7(2019)Part 4 Page Start: P249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. [P4–575]: ALZ‐801 MECHANISM OF ACTION: STOICHIOMETRY OF BETA AMYLOID ANTI‐OLIGOMER EFFECT, PK/PD, AND CLINICAL DOSE SELECTION FOR CONFIRMATORY PHASE 3 PROGRAM IN ALZHEIMER's DISEASE. (1st July 2017) Authors: Hey, John; Kocis, Petr; Abushakra, Susan; Yu, Jeremy; Power, Aidan; Blennow, Kaj; Tolar, Martin Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 32 Page Start: P1573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. [P4–585]: NOVEL ENVELOPING MECHANISM OF ACTION OF ALZ‐801: CONFORMATIONAL STABILIZATION OF BETA AMYLOID BY A SMALL MOLECULE RESULTS IN ANTI‐OLIGOMER ACTIVITY. (1st July 2017) Authors: Kocis, Petr; Tolar, Martin; Blennow, Kaj; Fillit, Howard M.; Hey, John Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 32 Page Start: P1578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P2‐012: Phase 1 Development of ALZ‐801, a Novel Beta Amyloid Anti‐Aggregation Prodrug of Tramiprosate with Improved Drug Properties, Supporting Bridging to The Phase 3 Program. (1st July 2016) Authors: Hey, John; Abushakra, Susan; Power, Aidan; Yu, Jeremy; Versavel, Mark; Tolar, Martin Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2016)Part 12 Page Start: P613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of Oral ALZ‐801, an Amyloid Oligomer Inhibitor, on Plasma Biomarkers in APOE4 Carriers with Early Alzheimer's Disease: Results of Six‐month Interim Analysis from a Phase 2 Biomarker Study. (20th December 2022) Authors: Abushakra, Susan; Hey, John; Blennow, Kaj; Scheltens, Philip; Reiman, Eric M.; Hort, Jakub; Sheardova, Katerina; Rutgers, Sterre M.; Prins, Niels D.; Dautzenberg, Paul; Pazdera, Ladislav; Power, Aidan; Tolar, Martin Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 10 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. [P1–052]: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4 HOMOZYGOTES WITH MILD TO MODERATE ALZHEIMER'S DISEASE (AD) ARE SUSTAINED OVER 130 WEEKS: RESULTS OF A PHASE 3 EXTENSION STUDY. (1st July 2017) Authors: Abushakra, Susan; Sadowsky, Carl H.; Porsteinsson, Anton P.; Gauthier, Serge; Vellas, Bruno; Power, Aidan; Shen, Larry; Wang, Peter; Hey, John; Tolar, Martin Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 5 Page Start: P256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗